FPIN's Clinical Inquiries

Risk of Gout with the Use of Thiazide Diuretics

 


FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.


FREE PREVIEW. Purchase online access to read the full version of this article.

Am Fam Physician. 2015 Oct 1;92(7):622-623.

Clinical Question

Does the use of thiazide diuretics increase the risk of gout?

Evidence-Based Answer

Thiazide diuretics may be used in most patients with hypertension who have only minimally increased risk of gout. (Strength of Recommendation [SOR]: B, based on a single randomized controlled trial [RCT].) There is no increased risk in patients older than 60 years or in women, but there is a slightly increased risk (about 1%) in men younger than 60 years (SOR: B, based on a single RCT.) Usual doses of thiazides (less than 25 mg) are not associated with an increased risk of gout, although doses of 25 mg or greater are. The risk of gout with hydrochlorothiazide and chlorthalidone is similar. Thiazides may be used in patients with asymptomatic hyperuricemia because they are not associated with an increased risk of gout in these patients. (SOR: C, based on retrospective cohort studies.)

Evidence Summary

A double-blinded RCT of patients 60 years and older (n = 822) found no difference in the incidence of gouty arthritis attacks in patients who received 25 mg of hydrochlorothiazide plus 50 mg of triamterene (Dyrenium) compared with those who received placebo.1 Most of the eight patients who developed gouty arthritis were men, seven received the thiazide combination, and all had higher pretreatment uric acid levels.

A single-blinded placebo-controlled RCT (23,582 patient-years) found that treatment with bendrof luazide (a thiazide available in Europe) was associated with a slight increase in medication discontinuation due to gout in younger men, but not in women.2 Weaknesses of this study included lack of blinding for clinicians and trial evaluators, and lack of comparison of treatment groups.

A retrospective cohort study of patients 65 years and older (n = 9,249) found no associated risk of anti-gout therapy initiation in patients who received lower doses of thiazides (relative risk [RR] = 1.78; 95% confidence interval [CI], 0.66 to 4.78 for doses less than 25 mg).3 However, higher doses were associated with gout symptoms (RR = 2.39; 95% CI, 1.29 to 4.43 for doses of 25 to 49 mg; RR = 2.41; 95% CI, 1.39 to 4.19 for doses of 50 mg or more). Another retrospective cohort study (n = 3,033) found no increased risk of first-time gout attacks in patients receiving hydrochlorothiazide vs. chlorthalidone.4 A third retrospective cohort study (n = 5,234) found no associated risk of gout in patients with elevated uric acid levels who received thiazides.5

Recommendations from Others

The 2012 American College of Rheumatology guidelines for the management of gout list thiazide diuretics as a prime example of urate-elevating medications.6 The task force panel recognized the benefits of thiazides for blood pressure control and improved mortality in patients with hypertension.

Copyright Family Physicians Inquiries Network. Used with permission.

Address correspondence to Connie Kraus, PharmD, at connie.kraus@wisc.edu. Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.

REFERENCES

show all references

1. Staessen J. The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. Am J Med. 1991;90(3A):50S–54S....

2. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet. 1981;2(8246):539–543.

3. Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol. 1997;50(8):953–959.

4. Wilson L, Nair KV, Saseen JJ. Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension. J Clin Hypertens (Greenwich). 2014;16(12):864–868.

5. Duskin-Bitan H, Cohen E, Goldberg E, et al. The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort. Clin Rheumatol. 2014;33(4):549–553.

6. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–1446.

Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review.

The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to http://www.fpin.org or email: questions@fpin.org.

This series is coordinated by John E. Delzell, Jr., MD, MSPH, Assistant Medical Editor.

A collection of FPIN's Clinical Inquiries published in AFP is available at http://www.aafp.org/afp/fpin.



 

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Dec 1, 2016

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article